- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
AbbVie Expands API Production in Illinois with $380M Investment
The pharma giant plans to build two new facilities to manufacture ingredients for neuroscience and obesity drugs.
Published on Feb. 24, 2026
Got story updates? Submit your updates here. ›
AbbVie has announced plans to invest $380 million to construct two new active pharmaceutical ingredient (API) production facilities at its existing campus in North Chicago, Illinois. The project is part of AbbVie's broader commitment to invest $100 billion in the U.S. over the next decade and will provide capacity to manufacture APIs for the company's next-generation neuroscience and obesity drug candidates. The new facilities are expected to be fully operational by 2029 and will integrate advanced manufacturing technologies and artificial intelligence.
Why it matters
AbbVie's significant investment in API production capacity demonstrates the company's focus on growing its neuroscience and obesity drug pipelines. The expansion will help AbbVie meet anticipated demand for these therapeutic areas, which are key strategic priorities for the company. The project also aligns with AbbVie's broader efforts to reshore API production from Europe and Asia to the U.S.
The details
The $380 million API expansion project will involve the construction of two new facilities at AbbVie's existing campus in North Chicago. The company plans to start construction soon, with both facilities expected to be fully operational by 2029. The new sites will integrate advanced manufacturing technologies and artificial intelligence. AbbVie has 10 neuroscience candidates in Phase 1 and 2 trials, making this therapeutic area a cornerstone of the company's clinical pipeline. While AbbVie's obesity pipeline is more limited, the company has indicated interest in acquiring additional obesity drug candidates. The API expansion is intended to provide the manufacturing capacity needed to support growth in both neuroscience and obesity.
- AbbVie broke ground on a $195 million API facility in North Chicago in September 2025.
- The two new $380 million API facilities are expected to be fully operational by 2029.
The players
AbbVie
A global biopharmaceutical company that develops and markets drugs in several therapeutic areas, including neuroscience and immunology.
What’s next
AbbVie plans to create at least 350 new full-time jobs in Illinois as part of this API expansion project and its broader $100 billion investment commitment in the U.S. over the next decade.
The takeaway
AbbVie's significant investment in API production capacity in Illinois underscores the company's strategic focus on growing its neuroscience and obesity drug pipelines. The project aligns with AbbVie's broader efforts to reshore critical manufacturing capabilities to the U.S. and create new high-skilled jobs in the process.
